Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1403 formulation 1+ additive · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.
Blood samples will be collected to determine the AUC0-inf of MK-1403 in plasma.
Blood samples will be collected to determine the AUC0-last of MK-1403 in plasma.
Blood samples will be collected to determine the Cmax of MK-1403 in plasma.
| Arm | Type | Description |
|---|---|---|
| MK-1403 formulation (FM) 1 + additive, Fed | EXPERIMENTAL | MK-1403 FM 1 + additive tablet administered once orally at study dose after a high-fat meal. |
| MK-1403 FM1 + additive, Fasted | EXPERIMENTAL | MK-1403 FM1 + additive tablet administered once orally at study dose in a fasted state. |
| MK-1403 FM2 + additive, Fed | EXPERIMENTAL | MK-1403 FM2 tablet + additive administered once orally at study dose after a high-fat meal. |
| Name | Type | Description |
|---|---|---|
| MK-1403 formulation (FM) 1 + additive | DRUG | Oral tablet |
| MK-1403 FM2 + additive | DRUG | Oral tablet |
Inclusion Criteria: * Is in good health * Has a body mass index (BMI) ≥ 18 and ≤ 32 kg/m\^2 Exclusion Criteria: * Has history of cancer (malignancy) * Has a history of significant multiple and/or severe allergies
MK-1403 formulation 1+ additive is an investigational small molecule being developed by Merck & Company, Inc. (MRK). It is currently in Phase 1 clinical development for use in healthy participants. The drug is also known as MK-1403 formulation (FM) 1 + additive.
MK-1403 formulation 1+ additive is being studied in healthy participants as part of early clinical development. The ongoing Phase 1 trial is designed to evaluate the drug in healthy volunteers, with no specific disease condition being targeted at this stage.
MK-1403 formulation 1+ additive is being developed by Merck & Company, Inc., a pharmaceutical company traded on the stock exchange under the ticker symbol MRK. The company is conducting a Phase 1 clinical trial of this investigational small molecule.
MK-1403 formulation 1+ additive is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants in the United States.
MK-1403 formulation 1+ additive is being evaluated in a single Phase 1 clinical trial with the identifier NCT07677163, titled "A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)." The trial is recruiting 15 healthy participants aged 18 years and older in the United States.
Yes, MK-1403 formulation 1+ additive is the same as MK-1403 formulation (FM) 1 + additive. These names refer to the same investigational drug being developed by Merck & Company, Inc. for use in healthy participants.